Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSI) Accumulated Expenses (2020 - 2026)

TriSalus Life Sciences has reported Accumulated Expenses over the past 5 years, most recently at $7.1 million for Q1 2026.

  • For Q1 2026, Accumulated Expenses fell 15.9% year-over-year to $7.1 million; the TTM value through Mar 2026 reached $7.1 million, down 15.9%, while the annual FY2025 figure was $8.1 million, 10.07% up from the prior year.
  • Accumulated Expenses for Q1 2026 was $7.1 million at TriSalus Life Sciences, down from $8.1 million in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $11.4 million in Q1 2024 and troughed at $6.4 million in Q4 2022.
  • A 5-year average of $8.1 million and a median of $7.6 million in 2024 define the central range for Accumulated Expenses.
  • Biggest five-year swings in Accumulated Expenses: soared 65.53% in 2023 and later crashed 30.32% in 2024.
  • Year by year, Accumulated Expenses stood at $6.4 million in 2022, then soared by 65.53% to $10.6 million in 2023, then plummeted by 30.32% to $7.4 million in 2024, then rose by 10.07% to $8.1 million in 2025, then fell by 12.71% to $7.1 million in 2026.
  • Business Quant data shows Accumulated Expenses for TLSI at $7.1 million in Q1 2026, $8.1 million in Q4 2025, and $6.8 million in Q3 2025.